IRIDEX/$IRIX
1D1W1MYTD1Y5YMAX
Capital at risk
About IRIDEX
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
- Ticker
- $IRIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 93
- Headquarters
- Mountain View, United States
- Website
- www.iridex.com
IRIDEX Metrics
BasicAdvanced
$12M
-
-$0.21
0.63
-
Price and volume
Market cap
$12M
Beta
0.63
52-week high
$1.65
52-week low
$0.61
Average daily volume
94K
Financial strength
Current ratio
1.819
Quick ratio
0.893
Long term debt to equity
1.064
Total debt to equity
1.103
Profitability
EBITDA (TTM)
-2.604
Gross margin (TTM)
35.92%
Net profit margin (TTM)
-6.88%
Operating margin (TTM)
-5.39%
Effective tax rate (TTM)
-4.48%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-5.90%
Return on equity (TTM)
-73.15%
Valuation
Price to revenue (TTM)
0.224
Price to book
-4.95
Price to tangible book (TTM)
-2.82
Price to free cash flow (TTM)
-5.776
Free cash flow yield (TTM)
-17.31%
Free cash flow per share (TTM)
-0.116
Growth
Revenue change (TTM)
3.68%
Earnings per share change (TTM)
-36.99%
3-year revenue growth (CAGR)
-2.93%
10-year revenue growth (CAGR)
1.20%
3-year earnings per share growth (CAGR)
-24.90%
10-year earnings per share growth (CAGR)
12.18%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.